Back to Resource Center

Evofem Biosciences announces last patient enrolled for AMPREVENCE, the phase 2b sexually transmitted infections trial of Amphora

Evofem Biosciences announces last patient enrolled for AMPREVENCE, the phase 2b sexually transmitted infections trial of Amphora

July 2019

Click to view Press Release

Click for full info +

Full Info:


Resource Type:

Press Release

Citation:

(2019, April 23). Cision PR Newswire.

Health Risks(s):

  • Chlamydia
  • Gonorrhea
  • Unintended Pregnancy

Product type(s):

  • MPTs
  • VaginalCream

Topic(s):

  • MPTs
  • Development

    Region(s)

    • Global

    URL of resource:

    https://www.prnewswire.com/news-releases/evofem-biosciences-announces-last-patient-enrolled-for-amprevence-the-phase-2b-sexually-transmitted-infections-trial-of-amphora-300836365.html?tc=portal_CAP

    Back to Resource Center